{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:02:14Z","timestamp":1789740134026,"version":"4.0.1"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010909","name":"Excellent Young Scientists Fund","doi-asserted-by":"publisher","award":["82022079"],"award-info":[{"award-number":["82022079"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Literature guiding the use of long-acting injectable antipsychotics (LAIAs) versus oral antipsychotics (OAs) in people with intellectual disability (PWID) remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Examining the associations of LAIAs vs OAs with healthcare utilisation among PWID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This self-controlled case series study used electronic health records from Hong Kong. We included adults with intellectual disability prescribed both LAIAs and OAs at different periods in 2004\u20132023. We compared within-individual LAIA and OA periods, adjusting for age, calendar year, season, inpatient stay and concomitant psychotropic use, using conditional Poisson regression to estimate incidence rate ratios (IRRs) for all-cause emergency department (ED) visits; all-cause hospitalisations; hospitalisations for psychiatric disorders, schizophrenia\/bipolar disorder, behaviour-related problems, somatic disorders and cardiovascular diseases (CVDs) and diagnosis records of extrapyramidal symptoms (EPS); falls and fractures. Subgroup analyses were conducted by diagnosis of schizophrenia or bipolar disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We identified 1675 PWID who had been prescribed both OAs and LAIAs at different periods during the study period. LAIA use was associated with lower risks of incident all-cause ED visits (adjusted IRR: 0.71, 95%\u2009CI 0.51 to 0.98), all-cause hospitalisations (0.91, 0.85\u20130.98); hospitalisations for psychiatric disorders (0.90, 0.81\u20130.99); for schizophrenia\/bipolar disorder (0.86, 0.75\u20130.99) and EPS (0.34, 0.23\u20130.51), compared with OAs. In PWID with schizophrenia\/bipolar disorder, LAIAs were associated with lower risks of all-cause hospitalisations, hospitalisations for psychiatric disorders, schizophrenia\/bipolar disorder, behaviour-related problems and somatic disorders, and EPS, but a higher risk of hospitalisations for CVDs (with hypertensive disease being the most common), compared with OAs. In contrast, among PWID without such diagnoses, LAIA use was associated with higher risks of all-cause hospitalisations, hospitalisations for somatic disorders; a lower risk of incident all-cause ED visits and hospitalisations for CVDs, but no significant difference in hospitalisations for behaviour-related problems, compared with OAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings are consistent with potential benefit of LAIAs among PWID with schizophrenia or bipolar disorder, while raising concern about off-label use in those without these diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>LAIAs may be considered in PWID with schizophrenia or bipolar disorder; off-label use in those without these diagnoses should be approached cautiously, and deprescribing may be considered where appropriate if these results are replicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302830","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:40:10Z","timestamp":1788871210000},"page":"e302830","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Differences in associations between long-acting injectable and oral antipsychotic prescribing and healthcare utilisation in people with intellectual disability: a self-controlled case series (LOID study)"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3102-9992","authenticated-orcid":false,"given":"Shek Ming","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"},{"name":"Institute of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent K C","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Kehui","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-8103","authenticated-orcid":false,"given":"Shoumitro","family":"Deb","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1580","authenticated-orcid":false,"given":"David","family":"Castle","sequence":"additional","affiliation":[{"name":"Centre for Mental Health Service Innovation, Tasmania Statewide Mental Health Services, Hobart, Tasmania, Australia"},{"name":"Department of Psychiatry, University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caige","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei Hang Edmund","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Sai-Yu","family":"Lui","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa W S","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-1959","authenticated-orcid":false,"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Family Medicine and Primary Care, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Ching","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kowloon Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China"},{"name":"Accident and Emergency Department, Queen Mary Hospital, Hong Kong, China"},{"name":"Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026091806105537000_29.1.e302830.1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000448912","article-title":"Intellectual Disability in a Birth Cohort: Prevalence, Etiology, and Determinants at the Age of 4 Years","volume":"19","author":"Karam","year":"2016","journal-title":"Public Health Genomics"},{"key":"2026091806105537000_29.1.e302830.2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/00048674251324824","article-title":"Prevalence of psychiatric conditions in people with intellectual disability: A record linkage study in New South Wales, Australia","volume":"59","author":"Arnold","year":"2025","journal-title":"Aust N Z J Psychiatry"},{"key":"2026091806105537000_29.1.e302830.3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J Psychiatry"},{"key":"2026091806105537000_29.1.e302830.4","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1431604","article-title":"Medication adherence among Japanese patients with developmental disabilities: a survey study","volume":"15","author":"Ando","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026091806105537000_29.1.e302830.5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/08039488.2021.1931714","article-title":"Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder - a naturalistic mirror image study","volume":"76","author":"Y\u0131ld\u0131zhan","year":"2022","journal-title":"Nord J Psychiatry"},{"key":"2026091806105537000_29.1.e302830.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24163","article-title":"Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia","volume":"5","author":"Wei","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026091806105537000_29.1.e302830.7","doi-asserted-by":"crossref","DOI":"10.1177\/20451253251367591","article-title":"Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study","volume":"15","author":"Brasso","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026091806105537000_29.1.e302830.8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2215-0366(25)00268-8","article-title":"Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis","volume":"12","author":"Wei","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091806105537000_29.1.e302830.9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0000000000000519","article-title":"Treatment adherence in forensic patients with schizophrenia spectrum disorders discharged on long-acting injectable antipsychotics: a comparative 3-year mirror-image study","volume":"39","author":"Balcioglu","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"key":"2026091806105537000_29.1.e302830.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-025-07620-7","article-title":"A whole population-based cohort study of the trajectory of the prevalence and the incidence of mental illness, challenging behaviour, and psychotropic medication prescribing in adults with intellectual disabilities in the Czech Republic between 2010 and 2022","volume":"25","author":"Deb","year":"2025","journal-title":"BMC Psychiatry"},{"key":"2026091806105537000_29.1.e302830.11","first-page":"91","article-title":"Medication management service for people with intellectual disabilities in Hong Kong: a descriptive analysis of prescribing patterns and pharmacists\u2019 interventions","volume":"50","author":"Li","year":"2024","journal-title":"Hong Kong J Ment Heal"},{"key":"2026091806105537000_29.1.e302830.12","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2009.tb00248.x"},{"key":"2026091806105537000_29.1.e302830.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-022-04479-w","article-title":"Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: a systematic review","volume":"23","author":"Adams","year":"2023","journal-title":"BMC Psychiatry"},{"key":"2026091806105537000_29.1.e302830.14","unstructured":"National Institute for Health and Care Excellence . Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11). 2015. Available: https:\/\/www.nice.org.uk\/guidance\/ng11"},{"key":"2026091806105537000_29.1.e302830.15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1080\/07853890.2022.2121853","article-title":"Management of psychotropic medications in adults with intellectual disability: a scoping review","volume":"54","author":"Costello","year":"2022","journal-title":"Ann Med"},{"key":"2026091806105537000_29.1.e302830.16","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s10803-024-06372-9","article-title":"Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability","volume":"56","author":"Simpson","year":"2026","journal-title":"J Autism Dev Disord"},{"key":"2026091806105537000_29.1.e302830.17","first-page":"2325","article-title":"Improvement of Behavioural Disorders in a Sample of Persons with Intellectual Disability after Administration of Paliperidone Palmitate","volume":"9","author":"Zamora-Rodriguez","year":"2019","journal-title":"Neuropsychiatry (London)"},{"key":"2026091806105537000_29.1.e302830.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60072-0"},{"key":"2026091806105537000_29.1.e302830.19","doi-asserted-by":"publisher","DOI":"10.3310\/hta13070"},{"key":"2026091806105537000_29.1.e302830.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017406","article-title":"Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study","volume":"7","author":"Sheehan","year":"2017","journal-title":"BMJ Open"},{"key":"2026091806105537000_29.1.e302830.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0070(86)80248-0"},{"key":"2026091806105537000_29.1.e302830.22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.18773\/austprescr.2016.048","article-title":"Prescribing psychotropic drugs to adults with an intellectual disability","volume":"39","author":"Trollor","year":"2016","journal-title":"Aust Prescr"},{"key":"2026091806105537000_29.1.e302830.23","unstructured":"Hong Kong Hospital Authority . Hospital authority about US. 2025. Available: https:\/\/www.ha.org.hk\/visitor\/ha_visitor_index.asp?Parent_ID=10005&Content_ID=10006&Ver=HTML"},{"key":"2026091806105537000_29.1.e302830.24","doi-asserted-by":"crossref","first-page":"101846","DOI":"10.1016\/j.ajp.2019.101846","article-title":"Prevalence of aggression in patients with schizophrenia: A systematic review and meta-analysis of observational studies","volume":"47","author":"Li","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"2026091806105537000_29.1.e302830.25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/20473869.2019.1640972","article-title":"Frequency and origin (reactive\/proactive) of aggressive behavior in young people with intellectual disability and autism spectrum disorder","volume":"67","author":"Oubrahim","year":"2019","journal-title":"Int J Dev Disabil"},{"key":"2026091806105537000_29.1.e302830.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"2026091806105537000_29.1.e302830.27","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"2026091806105537000_29.1.e302830.28","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw038","article-title":"Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials","volume":"19","author":"Kishi","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026091806105537000_29.1.e302830.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-025-00642-w","article-title":"Prevalence of cardiovascular risk factors and disease in patients with schizophrenia: baseline results from a prospective cohort study with long-term clinical follow-up","volume":"11","author":"Polcwiartek","year":"2025","journal-title":"Schizophrenia (Heidelb)"},{"key":"2026091806105537000_29.1.e302830.30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/104012371102300107","article-title":"Cardiovascular morbidity and mortality in bipolar disorder","volume":"23","author":"Weiner","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"2026091806105537000_29.1.e302830.31","doi-asserted-by":"crossref","first-page":"104968","DOI":"10.1016\/j.ridd.2025.104968","article-title":"Pattern of psychotropic prescribing in adults with intellectual disabilities in the community settings in the UK: A cross-sectional view","volume":"160","author":"Deb","year":"2025","journal-title":"Res Dev Disabil"},{"key":"2026091806105537000_29.1.e302830.32","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"2026091806105537000_29.1.e302830.33","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116636545"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:11:41Z","timestamp":1789737101000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjment-2026-302830"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302830","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}